Every 10-Q that SeaStar Medical Holding Corporation (ICU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ICU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICU filings page.
SeaStar Medical Holding Corporation reported continued early commercial progress but significant losses for the three and six months ended June 30, 2026. Net revenue was $615,000 in the quarter and $1.11 million year-to-date, up from $338,000 and $631,000 a year earlier, driven by increased adoption of its FDA-approved pediatric QUELIMMUNE therapy for acute kidney injury.
The company remains deeply loss-making. It recorded a net loss of $3.7 million for the quarter and $7.3 million for the first half of 2026, with operating expenses of $4.4 million in the quarter largely from research and development on its adult SCD program and general and administrative costs. Cash declined to $7.0 million at June 30, 2026, down from $12.0 million at year-end, and operating activities used $5.8 million of cash in the first half.
Management states that existing cash will not fund operations, including clinical trials, for 12 months and that this raises substantial doubt about the company’s ability to continue as a going concern. SeaStar is relying on equity financing facilities, including an at-the-market program and a standby equity purchase agreement, and has raised modest additional capital, while advancing pivotal adult AKI and other clinical studies on its SCD platform.
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.
SeaStar Medical Holding Corp. (ICU) reported Q3 2025 results showing early commercial traction and a strengthened balance sheet, alongside continued operating losses. Net revenue was $183 thousand for the quarter and $814 thousand for the first nine months, reflecting initial sales of QUELIMMUNE, the FDA-approved pediatric SCD therapy. Q3 net loss was $3.5 million, improving from $4.5 million a year ago, as operating expenses declined.
Cash rose to $13.8 million as of September 30, 2025, up from $1.8 million at year-end, driven by equity financings and warrant exercises. Stockholders’ equity improved to $11.5 million from a deficit at December 31, 2024, with 34.1 million shares outstanding at quarter-end and 36.0 million as of November 7, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting that additional capital is needed to fund operations and clinical programs. Subsequent to quarter-end, the company raised $1.2 million gross via its ATM and financed its D&O insurance with a short-term note.
SeaStar Medical Holding Corporation (ICU) reported early commercial sales of its pediatric SCD product QUELIMMUNE, recognizing $338 thousand in revenue for the quarter and $631 thousand for the six months ended June 30, 2025. Gross profit was $311 thousand for the quarter and $604 thousand for six months; cost of goods sold was $27 thousand. The company recorded a net loss of $2.0 million for the quarter and $5.8 million for the six months, with a weighted-average share base of 11.33 million and basic and diluted net loss per share of $(0.18) and $(0.58), respectively.
The balance sheet shows $6.3 million in cash and $8.4 million in total assets as of June 30, 2025, and an accumulated deficit of $145.3 million. Management states it does not believe existing cash is sufficient to fund operations for 12 months and discloses substantial doubt about going concern. The filing details multiple 2025 equity financings (February, June, ATM proceeds) and subsequent July/August 2025 registered offerings, and notes receipt of a Nasdaq notice for bid-price noncompliance with a cure period to January 27, 2026.